Pyxis Oncology (NASDAQ: PYXS) sees GordonMD entities report over 10M shares and large warrant stake
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
GordonMD Global Investments LP and related entities filed an initial ownership report for Pyxis Oncology, Inc.. Through GordonMD Long Biased Master Fund LP, they report indirect holdings of 10,024,909 shares of common stock. They also report a Common Stock Purchase Warrant directly held for up to 4,900,039 underlying shares at an exercise price of $3.289 per share, expiring on July 2, 2029. The warrant becomes exercisable on the earlier of the Issuer’s first public disclosure of clinical data from its MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC or October 1, 2026. The Master Fund, its general partner, and Craig D. Gordon each disclaim beneficial ownership beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
GordonMD Global Investments LP, GordonMD Long Biased Master Fund LP, GordonMD Long Biased GP LLC, Gordon Craig D
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock Purchase Warrant | -- | -- | -- |
| holding | Common Stock, par value $0.001 per share | -- | -- | -- |
Holdings After Transaction:
Common Stock Purchase Warrant — 4,900,039 shares (Direct);
Common Stock, par value $0.001 per share — 10,024,909 shares (Indirect, See footnote)
Footnotes (1)
- The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. The Common Stock Purchase Warrant is exercisable on or after the earlier of (i) the date on which the Issuer first publicly discloses clinical data from its micvotabart pelidotin (MICVO) Phase 1 monotherapy study in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) and (ii) October 1, 2026. Exercise price of $3.289, subject to adjustments as set forth in the Common Stock Purchase Warrant.
Key Figures
Common stock held: 10,024,909 shares
Warrant underlying shares: 4,900,039 shares
Warrant exercise price: $3.289 per share
+2 more
5 metrics
Common stock held
10,024,909 shares
Indirectly held through GordonMD Long Biased Master Fund LP as reported beneficial ownership
Warrant underlying shares
4,900,039 shares
Underlying common shares for the reported Common Stock Purchase Warrant
Warrant exercise price
$3.289 per share
Exercise price of the Common Stock Purchase Warrant, subject to adjustments
Warrant expiration
July 2, 2029
Expiration date of the Common Stock Purchase Warrant
Latest warrant exercisability date
October 1, 2026
Latest date by which the warrant becomes exercisable if earlier clinical data trigger has not occurred
Key Terms
Common Stock Purchase Warrant, exercise price, beneficial ownership, pecuniary interest, +1 more
5 terms
Common Stock Purchase Warrant financial
"The Common Stock Purchase Warrant is exercisable on or after the earlier of..."
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
exercise price financial
"Exercise price of $3.289, subject to adjustments as set forth..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
beneficial ownership financial
"disclaims beneficial ownership of the securities to which this filing relates..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his or its pecuniary interest therein, if any."
Section 16 regulatory
"for purposes of Section 16 of the Securities and Exchange Act of 1934..."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What warrant position in PYXS is disclosed in this Form 3?
The reporting persons disclose a Common Stock Purchase Warrant for up to 4,900,039 underlying common shares, with an exercise price of $3.289 per share and an expiration date of July 2, 2029.
When does the reported PYXS Common Stock Purchase Warrant become exercisable?
The warrant becomes exercisable on the earlier of the date Pyxis first publicly discloses clinical data from its MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC or October 1, 2026.
How do the GordonMD entities describe their beneficial ownership of PYXS securities?
The Master Fund, its general partner, and Craig D. Gordon each disclaim beneficial ownership of the reported securities for Section 16 purposes, except to the extent of their pecuniary interest in those holdings, if any.